Phase I study of copanlisib combined with venetoclax in relapsed/refractory diffuse large B-cell lymphoma

A two-drug combination shows manageable side effects and encouraging responses in blood cancer patients.

What the study was

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.